Sunday, February 1, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Automotive & E-Mobility

Alphabet’s Valuation Boosted by Autonomous Driving Ambitions

Robert Sasse by Robert Sasse
February 1, 2026
in Automotive & E-Mobility, Earnings, Nasdaq, Tech & Software
0
Alphabet Stock
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

Alphabet Inc. finds itself at the center of investor attention this week, propelled by two significant developments. A potential multi-billion dollar funding round for its self-driving subsidiary, Waymo, could dramatically revalue the company’s “Other Bets” portfolio. Simultaneously, the market awaits the tech giant’s quarterly earnings report, which will test the enduring strength of its core advertising business.

Legal Relief and Market Momentum

As trading commenced, Alphabet’s stock hovered near recent peaks, closing the previous session at $338.76—a fresh 52-week high. The company received additional positive momentum from a legal ruling late last week. A U.S. federal judge rejected a request to impose a further $2.36 billion in penalties on Alphabet in the “Rodriguez v. Google LLC” case concerning app data privacy settings. While a jury had previously awarded $425 million in damages, the judge blocked a significant expansion of the penalty through disgorgement. This decision caps the financial exposure from the lawsuit at a far lower level than the worst-case scenario had suggested.

Waymo Seeks Massive Funding at Lofty Valuation

Reports emerging over the weekend indicate that Waymo, Alphabet’s autonomous vehicle unit, is planning a substantial capital raise. The funding round is targeting approximately $16 billion, which would value the subsidiary at nearly $110 billion.

A notable aspect of the deal is that Alphabet itself is expected to provide the majority of the capital, with an investment of around $13 billion. External investors, including the venture capital firm Sequoia Capital, are also reportedly participating. This move sends a strong signal about Alphabet’s strategic commitment to autonomous driving. Rather than treating it as a mere speculative venture, the parent company appears to be doubling down on the technology as a core, long-term strategic pillar, despite its known capital intensity.

Should investors sell immediately? Or is it worth buying Alphabet?

Key Details of the Prospective Funding:
– Target Raise: ~$16 billion
– Proposed Waymo Valuation: ~$110 billion
– Alphabet’s Expected Contribution: ~$13 billion
– Noted External Investor: Sequoia Capital

Earnings Report to Test Core Business Strength

All eyes now turn to Alphabet’s fourth-quarter results, scheduled for release on Wednesday, February 4. Wall Street maintains a constructive outlook ahead of the report. Bank of America analyst Justin Post recently reaffirmed his “Buy” rating and a $370 price target.

Consensus estimates for the quarter are well-defined, placing the focus squarely on Alphabet’s primary revenue engines:
– Revenue: Bank of America projects $95.9 billion (Consensus: $95.2 billion)
– Earnings Per Share (EPS): Approximately $2.65
– Key Growth Drivers: YouTube revenue growth of 14–15% and Search revenue growth of 15–16%, according to forecasts.

While the Waymo news fuels long-term valuation narratives, the immediate market reaction will likely be dictated by the performance of Search, YouTube, and Cloud. The company’s ability to meet or exceed high expectations in these established segments remains the critical near-term catalyst for its share price.

Ad

Alphabet Stock: Buy or Sell?! New Alphabet Analysis from February 1 delivers the answer:

The latest Alphabet figures speak for themselves: Urgent action needed for Alphabet investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 1.

Alphabet: Buy or sell? Read more here...

Tags: Alphabet
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Cadence Design Stock
AI & Quantum Computing

Cadence Design Shares Face Critical Earnings Test

February 1, 2026
Warner Bros. Discovery (A) Stock
Market Commentary

Acquisition Battle Intensifies for Warner Bros. Discovery

February 1, 2026
Synopsys Stock
AI & Quantum Computing

Synopsys Stock: The Integration Challenge Takes Center Stage

February 1, 2026
Next Post
Diginex Stock

Diginex Pivots to Sustainability Tech with New Leadership

Rocket Lab USA Stock

Rocket Lab Advances Neutron Rocket Development Amid Shifting Market Conditions

Synopsys Stock

Synopsys Stock: The Integration Challenge Takes Center Stage

Recommended

Healthcare cloud based

Consistent Confidence in UnitedHealth Group RBC Capital Analyst Reiterates Outperform Rating and 596 Price Target

2 years ago
DB Gold Double Long ETN Stock

Leveraged Gold ETN Surges Amid Precious Metal Boom

4 months ago
Uranium Energy Stock

Uranium Energy Stock Gains Strategic Advantage with U.S. Policy Shift

3 months ago
Home Construction Stock Exchange

Vulcan Materials Co Reveals Financial Outlook for Fiscal Year 2024

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Synopsys Stock: The Integration Challenge Takes Center Stage

Rocket Lab Advances Neutron Rocket Development Amid Shifting Market Conditions

Diginex Pivots to Sustainability Tech with New Leadership

Alphabet’s Valuation Boosted by Autonomous Driving Ambitions

Almonty Industries Approaches All-Time High on Operational Milestones

Fiserv Deepens AI Integration Through Expanded ServiceNow Alliance

Trending

Intellia Therapeutics Stock
Analysis

Intellia Therapeutics Clears Key Regulatory Obstacle for Gene Therapy Trial

by Andreas Sommer
February 1, 2026
0

A significant regulatory roadblock has been removed for Intellia Therapeutics. The U.S. Food and Drug Administration (FDA)...

Cadence Design Stock

Cadence Design Shares Face Critical Earnings Test

February 1, 2026
Warner Bros. Discovery (A) Stock

Acquisition Battle Intensifies for Warner Bros. Discovery

February 1, 2026
Synopsys Stock

Synopsys Stock: The Integration Challenge Takes Center Stage

February 1, 2026
Rocket Lab USA Stock

Rocket Lab Advances Neutron Rocket Development Amid Shifting Market Conditions

February 1, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Intellia Therapeutics Clears Key Regulatory Obstacle for Gene Therapy Trial
  • Cadence Design Shares Face Critical Earnings Test
  • Acquisition Battle Intensifies for Warner Bros. Discovery

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com